NFAT is a primary transcription factor for T cell activation. Soluble IL-2 receptor, a marker of T cell activation, is found to be elevated in 20 out of 21 cases of iMCD. (Liu et al)
There are no existing therapies that target NFAT.
Clinical Trials targeting NFAT in iMCD patients:
No clinical trials targeting NFAT in iMCD patients have been conducted.